Cargando…

Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) poses a serious threat to healthcare systems worldwide. Binding of the virus to angiotensin‐converting enzyme 2 (ACE2) is an important step in the infection mechanism. However, it is unknown if ACE2 expression in patients with chronic lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Fließer, Elisabeth, Birnhuber, Anna, Marsh, Leigh M, Gschwandtner, Elisabeth, Klepetko, Walter, Olschewski, Horst, Kwapiszewska, Grazyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239572/
https://www.ncbi.nlm.nih.gov/pubmed/33978304
http://dx.doi.org/10.1002/cjp2.224
_version_ 1783715095086366720
author Fließer, Elisabeth
Birnhuber, Anna
Marsh, Leigh M
Gschwandtner, Elisabeth
Klepetko, Walter
Olschewski, Horst
Kwapiszewska, Grazyna
author_facet Fließer, Elisabeth
Birnhuber, Anna
Marsh, Leigh M
Gschwandtner, Elisabeth
Klepetko, Walter
Olschewski, Horst
Kwapiszewska, Grazyna
author_sort Fließer, Elisabeth
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) poses a serious threat to healthcare systems worldwide. Binding of the virus to angiotensin‐converting enzyme 2 (ACE2) is an important step in the infection mechanism. However, it is unknown if ACE2 expression in patients with chronic lung diseases (CLDs), such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary arterial hypertension (IPAH), or pulmonary fibrosis (PF), is changed as compared to controls. We used lung samples from patients with COPD (n = 28), IPAH (n = 10), and PF (n = 10) as well as healthy control donor (n = 10) tissue samples to investigate the expression of ACE2 and related cofactors that might influence the course of SARS‐CoV‐2 infection. Expression levels of the ACE2 receptor, the putative receptor CD147/BSG, and the viral entry cofactors TMPRSS2 (transmembrane serine protease 2), EZR, and FURIN were determined by quantitative PCR and in open‐access RNA sequencing datasets. Immunohistochemical and single‐cell RNA sequencing (scRNAseq) analyses were used for localization and coexpression, respectively. Soluble ACE2 (sACE2) plasma levels were analyzed by enzyme‐linked immunosorbent assay. In COPD as compared to donor, IPAH, and PF lung tissue, gene expression of ACE2, TMPRSS2, and EZR was significantly elevated, but circulating sACE2 levels were significantly reduced in COPD and PF plasma compared to healthy control and IPAH plasma samples. Lung tissue expressions of FURIN and CD147/BSG were downregulated in COPD. None of these changes were associated with changes in pulmonary hemodynamics. Histological analysis revealed coexpression of ACE2, TMPRSS2, and Ezrin in bronchial regions and epithelial cells. This was confirmed by scRNAseq analysis. There were no significant expression changes of the analyzed molecules in the lung tissue of IPAH and idiopathic PF as compared to control. In conclusion, we reveal increased ACE2 and TMPRSS2 expression in lung tissue with a concomitant decrease of protective sACE2 in COPD patients. These changes represent the possible risk factors for an increased susceptibility of COPD patients to SARS‐CoV‐2 infection.
format Online
Article
Text
id pubmed-8239572
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-82395722021-06-29 Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD Fließer, Elisabeth Birnhuber, Anna Marsh, Leigh M Gschwandtner, Elisabeth Klepetko, Walter Olschewski, Horst Kwapiszewska, Grazyna J Pathol Clin Res Original Articles Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) poses a serious threat to healthcare systems worldwide. Binding of the virus to angiotensin‐converting enzyme 2 (ACE2) is an important step in the infection mechanism. However, it is unknown if ACE2 expression in patients with chronic lung diseases (CLDs), such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary arterial hypertension (IPAH), or pulmonary fibrosis (PF), is changed as compared to controls. We used lung samples from patients with COPD (n = 28), IPAH (n = 10), and PF (n = 10) as well as healthy control donor (n = 10) tissue samples to investigate the expression of ACE2 and related cofactors that might influence the course of SARS‐CoV‐2 infection. Expression levels of the ACE2 receptor, the putative receptor CD147/BSG, and the viral entry cofactors TMPRSS2 (transmembrane serine protease 2), EZR, and FURIN were determined by quantitative PCR and in open‐access RNA sequencing datasets. Immunohistochemical and single‐cell RNA sequencing (scRNAseq) analyses were used for localization and coexpression, respectively. Soluble ACE2 (sACE2) plasma levels were analyzed by enzyme‐linked immunosorbent assay. In COPD as compared to donor, IPAH, and PF lung tissue, gene expression of ACE2, TMPRSS2, and EZR was significantly elevated, but circulating sACE2 levels were significantly reduced in COPD and PF plasma compared to healthy control and IPAH plasma samples. Lung tissue expressions of FURIN and CD147/BSG were downregulated in COPD. None of these changes were associated with changes in pulmonary hemodynamics. Histological analysis revealed coexpression of ACE2, TMPRSS2, and Ezrin in bronchial regions and epithelial cells. This was confirmed by scRNAseq analysis. There were no significant expression changes of the analyzed molecules in the lung tissue of IPAH and idiopathic PF as compared to control. In conclusion, we reveal increased ACE2 and TMPRSS2 expression in lung tissue with a concomitant decrease of protective sACE2 in COPD patients. These changes represent the possible risk factors for an increased susceptibility of COPD patients to SARS‐CoV‐2 infection. John Wiley & Sons, Inc. 2021-05-12 /pmc/articles/PMC8239572/ /pubmed/33978304 http://dx.doi.org/10.1002/cjp2.224 Text en © 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Fließer, Elisabeth
Birnhuber, Anna
Marsh, Leigh M
Gschwandtner, Elisabeth
Klepetko, Walter
Olschewski, Horst
Kwapiszewska, Grazyna
Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD
title Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD
title_full Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD
title_fullStr Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD
title_full_unstemmed Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD
title_short Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD
title_sort dysbalance of ace2 levels – a possible cause for severe covid‐19 outcome in copd
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239572/
https://www.ncbi.nlm.nih.gov/pubmed/33978304
http://dx.doi.org/10.1002/cjp2.224
work_keys_str_mv AT fließerelisabeth dysbalanceoface2levelsapossiblecauseforseverecovid19outcomeincopd
AT birnhuberanna dysbalanceoface2levelsapossiblecauseforseverecovid19outcomeincopd
AT marshleighm dysbalanceoface2levelsapossiblecauseforseverecovid19outcomeincopd
AT gschwandtnerelisabeth dysbalanceoface2levelsapossiblecauseforseverecovid19outcomeincopd
AT klepetkowalter dysbalanceoface2levelsapossiblecauseforseverecovid19outcomeincopd
AT olschewskihorst dysbalanceoface2levelsapossiblecauseforseverecovid19outcomeincopd
AT kwapiszewskagrazyna dysbalanceoface2levelsapossiblecauseforseverecovid19outcomeincopd